Investor Update: Edenville Energy announces two big new offtake deals for its coal

Headlines from the Proactive UK newsroom.

Edenville Energy’s (LON:EDL) signed two new significant contracts to supply washed coal from flagship Rukwa Coal Project in Tanzania. The new deals represent a supply of up to 9,000 tonnes per month, which is roughly 75% of the current capacity of the recently refurbished wash plant. 

Faron Pharmaceuticals (LON:FARN) is to present trial data for its Clevegen treatment that indicates it can reduce a range of the checkpoint inhibitors that supress a person’s immune response to cancer. One of the body’s main tools to fight the disease also received a boost.

Nuclear detection group Kromek (LON:KMK) increased half year sales by 43% to a record £5.3mln.The company is predicting further significant revenue growth for the full year.

Savannah Resources (LON:SAV) has received its second mining licence for the Mutamba Heavy Mineral Sands Project in Mozambique. Savannah is in a joint venture with Rio Tinto and is waiting for the third and final licence to be awarded to move forward with the project.

Stagecoach’s founder is to step down as chairman at the end of year with Ray O’Toole to take over. Interim revenues dropped by 21% as the rail operation wound down though London buses performed better than expected.

An all-electric powered flight by a seaplane has been described as a new era for aviation. The flight took place in Vancouver and its developer HarbourAir hopes to turn its entire seaplane fleet electric by 2022.

Embattled over-fifties cruise and insurance group Saga has appointed former Superdry boss Euan Sutherland as its new chief executive. He replaces Lance Batchelor who is retiring.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

14 hours, 15 minutes ago

2 min read